MA33134B1 - Derives d'indole en tant qu'antagonistes du recepteur crth2 - Google Patents
Derives d'indole en tant qu'antagonistes du recepteur crth2Info
- Publication number
- MA33134B1 MA33134B1 MA34181A MA34181A MA33134B1 MA 33134 B1 MA33134 B1 MA 33134B1 MA 34181 A MA34181 A MA 34181A MA 34181 A MA34181 A MA 34181A MA 33134 B1 MA33134 B1 MA 33134B1
- Authority
- MA
- Morocco
- Prior art keywords
- receptor antagonists
- indole derivatives
- crth2 receptor
- crth2
- pgd2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention porte sur des composés de formule (I) qui sont des antagonistes du récepteur PGD2, CRTH2, et qui, en tant que tels, sont utiles dans le traitement et/ou la prévention de maladies à médiation par CRTH2 telles que l'asthme.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15496809P | 2009-02-24 | 2009-02-24 | |
PCT/US2010/024713 WO2010099039A1 (fr) | 2009-02-24 | 2010-02-19 | Dérivés d'indole en tant qu'antagonistes du récepteur crth2 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33134B1 true MA33134B1 (fr) | 2012-03-01 |
Family
ID=42046150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34181A MA33134B1 (fr) | 2009-02-24 | 2010-02-19 | Derives d'indole en tant qu'antagonistes du recepteur crth2 |
Country Status (37)
Country | Link |
---|---|
US (2) | US8394819B2 (fr) |
EP (2) | EP2401269B1 (fr) |
JP (1) | JP4989786B1 (fr) |
KR (2) | KR101276530B1 (fr) |
CN (1) | CN102333771B (fr) |
AR (1) | AR075597A1 (fr) |
AU (1) | AU2010218209B2 (fr) |
BR (1) | BRPI1008906B1 (fr) |
CA (1) | CA2752981C (fr) |
CL (1) | CL2011002056A1 (fr) |
CO (1) | CO6410295A2 (fr) |
CR (1) | CR20110455A (fr) |
DK (1) | DK2401269T3 (fr) |
DO (1) | DOP2011000271A (fr) |
EA (1) | EA021076B1 (fr) |
EC (1) | ECSP11011288A (fr) |
ES (2) | ES2529420T3 (fr) |
HK (1) | HK1160465A1 (fr) |
HN (1) | HN2011002272A (fr) |
HR (1) | HRP20140384T1 (fr) |
IL (1) | IL214342A0 (fr) |
MA (1) | MA33134B1 (fr) |
MX (1) | MX2011008869A (fr) |
MY (1) | MY152062A (fr) |
NI (1) | NI201100162A (fr) |
NZ (1) | NZ594767A (fr) |
PE (1) | PE20120056A1 (fr) |
PL (1) | PL2401269T3 (fr) |
PT (1) | PT2401269E (fr) |
RS (1) | RS53268B (fr) |
SG (1) | SG173775A1 (fr) |
SI (1) | SI2401269T1 (fr) |
TN (1) | TN2011000382A1 (fr) |
TW (2) | TWI454474B (fr) |
UA (1) | UA105039C2 (fr) |
WO (1) | WO2010099039A1 (fr) |
ZA (1) | ZA201105767B (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009295230A1 (en) * | 2008-09-22 | 2010-03-25 | Merck Canada Inc. | Indole derivatives as CRTH2 receptor antagonists |
WO2010031184A1 (fr) * | 2008-09-22 | 2010-03-25 | Merck Frosst Canada Ltd. | Dérivés d'azaindole comme antagonistes du récepteur crth2 |
US9469615B2 (en) | 2010-12-23 | 2016-10-18 | Merck Sharp & Dohme Corp. | Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators |
US9290453B2 (en) | 2010-12-23 | 2016-03-22 | Merck Sharp & Dohme Corp. | Quinolines and aza-quinolines as CRTH2 receptor modulators |
DK2697223T3 (en) * | 2011-04-14 | 2016-09-05 | Actelion Pharmaceuticals Ltd | 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor |
AU2012271661B8 (en) * | 2011-06-17 | 2016-11-10 | Merck Sharp & Dohme Corp. | Cycloalkyl-fused tetrahydroquinolines as CRTH2 receptor modulators |
US20130072470A1 (en) | 2011-09-21 | 2013-03-21 | Abbvie Inc. | Novel tricyclic compounds |
CN103450218B (zh) * | 2012-05-29 | 2015-12-23 | 山东亨利医药科技有限责任公司 | 作为crth2受体拮抗剂的吲哚类三并环衍生物 |
US9290454B2 (en) | 2012-10-01 | 2016-03-22 | Merck Sharp & Dohme Corp. | Substituted isoquinolines as CRTH2 receptor modulators |
WO2014060596A1 (fr) * | 2012-10-18 | 2014-04-24 | Zach System S.P.A. | Procédé de préparation de dérivés d'indole |
MX368179B (es) | 2014-03-17 | 2019-09-23 | Idorsia Pharmaceuticals Ltd | Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2. |
MX2016011900A (es) | 2014-03-18 | 2016-12-05 | Actelion Pharmaceuticals Ltd | Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2. |
EP3954710A3 (fr) | 2015-04-02 | 2022-07-20 | Intervet International B.V. | Anticorps dirigés contre le récepteur alpha de l'interleukine-4 canine |
WO2017005759A1 (fr) | 2015-07-07 | 2017-01-12 | Intervet International B.V. | Procédé pour produire des dérivés d'azaindole |
WO2017005764A1 (fr) * | 2015-07-07 | 2017-01-12 | Intervet International B.V. | Procédé de production d'intermédiaires tricyclocétones d'antagonistes de crth2 |
WO2017005766A1 (fr) | 2015-07-07 | 2017-01-12 | Intervet International B.V. | Procédé de production d'intermédiaires alcools tricycliques d'antagonistes de crth2 |
MX2018000947A (es) | 2015-07-23 | 2018-06-07 | Merck Sharp & Dohme | Marcadores geneticos asociados con la respuesta a los antagonistas del receptor crth2. |
PL3350179T3 (pl) | 2015-09-15 | 2021-08-02 | Idorsia Pharmaceuticals Ltd | Krystaliczne postacie |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
BR122022024925B1 (pt) | 2015-10-16 | 2023-11-28 | Abbvie Inc | Composição farmacêutica de liberação prolongada compreendendo (3s,4r)-3-etil-4-(3h-imidazo[1,2-a]pirrolo[2,3-e]pirazin-8-il)-n-(2,2,2-trifluoroetil) pirroli-dina-1-carboxamida |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
AU2017375590A1 (en) | 2016-12-14 | 2019-06-13 | Beijing Genomics Institute At Shenzhen | Human genetic markers associated with response to treatments that target Clostridium difficile toxin B |
AU2020407269A1 (en) | 2019-12-20 | 2022-06-16 | Intervet International B.V. | Bispecific caninized antibodies for treating atopic dermatitis |
AU2022331122A1 (en) | 2021-08-20 | 2024-02-15 | Intervet International B.V. | Homodimer fusion proteins for treating atopic dermatitis |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
US5510332A (en) | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
DE69530392D1 (de) | 1994-07-11 | 2003-05-22 | Athena Neurosciences Inc | Inhibitoren der leukozytenadhäsion |
US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
WO1996031206A2 (fr) | 1995-04-07 | 1996-10-10 | Warner-Lambert Company | Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose |
WO1996040781A1 (fr) | 1995-06-07 | 1996-12-19 | Tanabe Seiyaku Co., Ltd. | INHIBITEURS PEPTIDIQUES CYCLIQUES D'ADHERENCE CELLULAIRE INDUITE PAR INTEGRINE β1 ET β¿2? |
AU6311996A (en) | 1995-07-06 | 1997-02-05 | Zeneca Limited | Peptide inhibitors of fibronectine |
US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
FR2827206B1 (fr) | 2001-07-10 | 2004-04-02 | Nature Bois Emballages | Procede et dispositif de formage de planchettes, et emballages comportant de telles planchettes |
AU2003231509A1 (en) | 2002-05-16 | 2003-12-02 | Shionogi And Co., Ltd. | Compound exhibiting pgd 2 receptor antagonism |
US20070054951A1 (en) * | 2003-05-20 | 2007-03-08 | Lianhai Li | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists |
PL1725553T3 (pl) * | 2004-03-11 | 2008-10-31 | Idorsia Pharmaceuticals Ltd | Pochodne tetrahydropirydoindolu |
WO2006015191A2 (fr) | 2004-07-29 | 2006-02-09 | Threshold Pharmaceuticals, Inc. | Analogues de lonidamine multicycliques |
GB0427381D0 (en) * | 2004-12-14 | 2005-01-19 | Novartis Ag | Organic compounds |
EP1833791B1 (fr) * | 2004-12-27 | 2011-08-03 | Actelion Pharmaceuticals Ltd. | Derives de 2,3,4,9-tetrahydro-1h-carbazole utilises en tant qu'antagonistes des recepteurs de crth2 |
GB0505048D0 (en) * | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
US7696222B2 (en) | 2005-08-12 | 2010-04-13 | Merck Frosst Canada Ltd | Indole derivatives as CRTH2 receptor antagonists |
NZ574705A (en) | 2006-08-07 | 2011-12-22 | Actelion Pharmaceuticals Ltd | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives |
US20110112134A1 (en) | 2008-05-16 | 2011-05-12 | Amira Pharmaceuticals, Inc. | Tricyclic Antagonists of Prostaglandin D2 Receptors |
WO2010031184A1 (fr) | 2008-09-22 | 2010-03-25 | Merck Frosst Canada Ltd. | Dérivés d'azaindole comme antagonistes du récepteur crth2 |
AU2009295230A1 (en) | 2008-09-22 | 2010-03-25 | Merck Canada Inc. | Indole derivatives as CRTH2 receptor antagonists |
JP2012502926A (ja) | 2008-09-22 | 2012-02-02 | メルク カナダ インコーポレイテッド | Crth2受容体アンタゴニストとしてのインドール誘導体 |
WO2010085820A2 (fr) | 2009-01-26 | 2010-07-29 | Amira Pharmaceuticals, Inc. | Composés tricycliques en tant qu'antagonistes des récepteurs d2 de la prostaglandine |
-
2010
- 2010-02-19 EP EP10705068.4A patent/EP2401269B1/fr active Active
- 2010-02-19 CA CA2752981A patent/CA2752981C/fr not_active Expired - Fee Related
- 2010-02-19 MX MX2011008869A patent/MX2011008869A/es active IP Right Grant
- 2010-02-19 KR KR1020137005315A patent/KR101276530B1/ko active IP Right Grant
- 2010-02-19 ES ES12168410.4T patent/ES2529420T3/es active Active
- 2010-02-19 RS RS20140213A patent/RS53268B/en unknown
- 2010-02-19 PE PE2011001523A patent/PE20120056A1/es not_active Application Discontinuation
- 2010-02-19 SI SI201030527T patent/SI2401269T1/sl unknown
- 2010-02-19 NZ NZ594767A patent/NZ594767A/xx not_active IP Right Cessation
- 2010-02-19 UA UAA201111313A patent/UA105039C2/uk unknown
- 2010-02-19 EA EA201171081A patent/EA021076B1/ru not_active IP Right Cessation
- 2010-02-19 PL PL10705068T patent/PL2401269T3/pl unknown
- 2010-02-19 ES ES10705068.4T patent/ES2450594T3/es active Active
- 2010-02-19 WO PCT/US2010/024713 patent/WO2010099039A1/fr active Application Filing
- 2010-02-19 PT PT107050684T patent/PT2401269E/pt unknown
- 2010-02-19 US US12/708,924 patent/US8394819B2/en active Active
- 2010-02-19 MA MA34181A patent/MA33134B1/fr unknown
- 2010-02-19 KR KR1020117019538A patent/KR101275980B1/ko active IP Right Grant
- 2010-02-19 DK DK10705068.4T patent/DK2401269T3/da active
- 2010-02-19 CN CN201080010563.9A patent/CN102333771B/zh not_active Expired - Fee Related
- 2010-02-19 AU AU2010218209A patent/AU2010218209B2/en not_active Ceased
- 2010-02-19 MY MYPI2011003785 patent/MY152062A/en unknown
- 2010-02-19 SG SG2011059912A patent/SG173775A1/en unknown
- 2010-02-19 JP JP2011550331A patent/JP4989786B1/ja not_active Expired - Fee Related
- 2010-02-19 EP EP12168410.4A patent/EP2492267B1/fr active Active
- 2010-02-19 BR BRPI1008906-3A patent/BRPI1008906B1/pt not_active IP Right Cessation
- 2010-02-23 TW TW099105206A patent/TWI454474B/zh not_active IP Right Cessation
- 2010-02-23 TW TW102128348A patent/TWI444381B/zh not_active IP Right Cessation
- 2010-02-24 AR ARP100100535A patent/AR075597A1/es not_active Application Discontinuation
-
2011
- 2011-07-28 IL IL214342A patent/IL214342A0/en unknown
- 2011-08-03 TN TN2011000382A patent/TN2011000382A1/fr unknown
- 2011-08-05 ZA ZA2011/05767A patent/ZA201105767B/en unknown
- 2011-08-23 CL CL2011002056A patent/CL2011002056A1/es unknown
- 2011-08-23 NI NI201100162A patent/NI201100162A/es unknown
- 2011-08-23 HN HN2011002272A patent/HN2011002272A/es unknown
- 2011-08-24 CR CR20110455A patent/CR20110455A/es unknown
- 2011-08-24 EC EC2011011288A patent/ECSP11011288A/es unknown
- 2011-08-24 DO DO2011000271A patent/DOP2011000271A/es unknown
- 2011-08-30 CO CO11111105A patent/CO6410295A2/es not_active Application Discontinuation
-
2012
- 2012-02-01 HK HK12100921.0A patent/HK1160465A1/xx not_active IP Right Cessation
-
2013
- 2013-02-07 US US13/762,050 patent/US9023864B2/en active Active
-
2014
- 2014-04-28 HR HRP20140384AT patent/HRP20140384T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33134B1 (fr) | Derives d'indole en tant qu'antagonistes du recepteur crth2 | |
ATE478072T1 (de) | Spiroimidazol-derivate als ppar-modulatoren | |
MA33730B1 (fr) | Procédés de synthèse pour des composés spiro-oxindoles | |
ATE394400T1 (de) | Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
MA32131B1 (fr) | Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine | |
MA33604B1 (fr) | Composés et compositions en tant qu'inhibiteurs de protéine kinase | |
GT200600093A (es) | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias | |
MA42145B1 (fr) | Triazoles agonistes du récepteur apj | |
TN2011000454A1 (fr) | Derives de benzofurannyle utilises comme inhibiteurs de glucokinase | |
MA31767B1 (fr) | Composes organiques et leurs utilisations | |
MA31457B1 (fr) | N-(2-(hetaryl)aryl)arylsulfonamides et n-(2-(hetaryl)hetaryl)arylsulfonamides | |
MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
MA34650B1 (fr) | Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane | |
ATE556060T1 (de) | Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten | |
MX2008012400A (es) | Azolopirimidinas como inhibidores de actividad de cannabinoide 1. | |
DE602007002792D1 (de) | Verbindungen und zusammensetzungen als ppar-modulatoren | |
MA30324B1 (fr) | Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine. | |
MA33926B1 (fr) | Aminopyrimidines en tant qu'inhibiteurs de la syk | |
NZ548954A (en) | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | |
DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
TW200612926A (en) | Compounds and compositions as ppar modulators | |
MA32975B1 (fr) | Antagonistes de c5ar | |
NO20065983L (no) | Forbindelser og sammensetninger som PPAR modulatorer | |
MX2007009356A (es) | Compuestos y composiciones como moduladores de ppar. |